Physician profile
Thomas L Shriwise
NPI 1861441859
$523.01
in general payments reported to CMS, 2019-2025
7 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $409 · 2021: $84.60 · 2023: $29.07.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $29.07.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $29.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zimmer Biomet Holdings, INC. | $158.55 | 2019 | |
| Linvatec Corporation | $121.88 | 2019 | |
| Horizon Therapeutics Plc | $108.73 | 2019-2021 | |
| Bioventus LLC | $44.15 | 2019 | |
| Anika Therapeutics, INC. | $40.56 | 2021 | |
| Titan Surgical Group, LLC | $29.07 | 2023 | |
| Depuy Synthes Sales INC. | $20.07 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Shriwise listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.